# US 2009/0269769 A1 · Drug Discovery Methods Involving A Preclinical, In Vitro Isolated Gastrointestinal Epithelial Stem Cell-Like Progenitor Cell System

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2009/0269769 A1
- Document ID: US20090269769A1
- Status: Published application
- Kind: A1
- Application number: 12/428,866
- Filed: 2009-04-23
- Published: 2009-10-29
- Earliest claimed: 2008-04-23
- Inventors: Asit Panja
- Web page: https://patentgrep.com/patent/US20090269769A1

## CPC

- G01N 33/5023: {on expression patterns}
- G01N 33/5044: {involving specific cell types}
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

The described invention relate to systems comprising isolated human gastrointestinal segment-specific epithelial stem cell-like progenitor cells and uses thereof in drug discovery.

## Claims

### Claim 1

A system to determine the segmental bioavailability of a therapeutic agent comprising differentiable gastrointestinal segment-specific human epithelial stem-cell-like progenitor cells isolated from at least one human mucosal tissue derived from at least one human gastrointestinal segment.

### Claim 2 (depends on 1)

The system according to claim 1, wherein the gastrointestinal segment-specific human epithelial stem cell-like progenitor cells are cultivated on a bio-similar matrix environment formed from the human mucosal tissue derived from the human gastrointestinal segment.

### Claim 3 (depends on 1)

The system according to claim 1, wherein the segment is a stomach segment.

### Claim 4 (depends on 1)

The system according to claim 1, wherein the segment is a jejunum segment.

### Claim 5 (depends on 1)

The system according to claim 1, wherein the segment is an ileum segment.

### Claim 6 (depends on 1)

The system according to claim 1, wherein the segment is a duodenum segment.

### Claim 7 (depends on 1)

The system according to claim 1, wherein the segment is an ascending colon segment.

### Claim 8 (depends on 1)

The system according to claim 1, wherein the segment is a transverse colon segment.

### Claim 9 (depends on 1)

The system according to claim 1, wherein the segment is a sigmoid colon segment.

### Claim 10 (depends on 1)

The system according to claim 1, wherein the segment is a rectum segment.

### Claim 11 (depends on 1)

The system according to claim 1, wherein the differentiable gastrointestinal segment-specific human epithelial stem-cell-like progenitor cell optionally differentiates into a mature cell phenotype.

### Claim 12 (depends on 1)

The system according to claim 1, wherein the mature cell phenotype is a columnar epithelial cell.

### Claim 13 (depends on 1)

The system according to claim 1, wherein the mature cell phenotype is a Paneth cell.

### Claim 14 (depends on 1)

The system according to claim 1, wherein the mature cell phenotype is a goblet cell.

### Claim 15 (depends on 1)

The system according to claim 1, wherein the mature cell phenotype is an enteroendocrine chromaffin cell

### Claim 16 (depends on 1)

The system according to claim 1, wherein the mature cell phenotype is a neuronal cell type.

### Claim 17 (depends on 1)

The system according to claim 1, wherein the differentiable gastrointestinal segment-specific human epithelial stem-cell-like progenitor cell is a mesenchymal cell.

### Claim 18 (depends on 1)

The system according to claim 1, wherein the system is used to assess at least one parameter of permeability of the therapeutic agent.

### Claim 19 (depends on 1)

The system according to claim 1, wherein the system is used to assess absorption of the therapeutic agent.

### Claim 20 (depends on 1)

The system according to claim 1, wherein the system is used to assess uptake of the therapeutic agent.

### Claim 21 (depends on 1)

The system according to claim 1, wherein the system is used to assess cellular toxicity of the therapeutic agent.

### Claim 22 (depends on 1)

The system according to claim 1, wherein the system is used to assess transepithelial electrical resistance.

### Claim 23 (depends on 1)

The system according to claim 1, wherein the differentiable gastrointestinal segment-specific human stem epithelial cell-like progenitor cells on the at least one bio-similar matrix environment are used to determine variations in DNA and/or RNA characteristics produced in response to the therapeutic agent.

### Claim 24 (depends on 1)

The system according to claim 1, wherein the system is used to determine segment-specific metabolic byproducts of the therapeutic agent.

### Claim 25 (depends on 1)

The system according to claim 1, wherein the bio-similar matrix environment formed from the at least one mucosal tissue derived from the stomach is serially connected to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the jejunum, which is serially connected to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the ileum, which is serially connected to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the duodenum, which is serially connected to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the ascending colon segment, which is serially connected to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the transverse colon segment, which is serially connected to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the sigmoid colon segment, which is serially connected to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the rectum to form an in vitro model of the human gastrointestinal tract

### Claim 26 (depends on 1)

The system according to claim 1, wherein the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cell has at least a β-1-integrin(+)cytokeratin(+) phenotype.

### Claim 27 (depends on 1)

The system according to claim 1, wherein the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cell has a phenotype of cytokeratin(+), β-1-integrin(+), defensin-5(+), trefoil factor-3(+), mucin-2(+), chomogranin-A(+), intestinal alkaline phosphatase(+), lysozyme(+).

### Claim 28

A method to determine gastrointestinal segmental effectiveness of a therapeutic agent, the method comprising the steps:
(a) isolating differentiable gastrointestinal segment-specific human epithelial stem-cell-like progenitor cells from at least one mucosal tissue derived from at least one human gastrointestinal segment;
(b) cultivating the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells on at least one bio-similar matrix environment formed from the at least one mucosal tissue derived from the at least one human gastrointestinal segment;
(c) exposing the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells on the at least one bio-similar matrix environment to the therapeutic agent; and
(d) analyzing the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells to determine regional specificity of the therapeutic agent.

### Claim 29 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is a stomach segment.

### Claim 30 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is a jejunum segment.

### Claim 31 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is an ileum segment.

### Claim 32 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is a duodenum segment.

### Claim 33 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is an ascending colon segment.

### Claim 34 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is a transverse colon segment.

### Claim 35 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is a sigmoid colon segment.

### Claim 36 (depends on 28)

The method according to claim 28, wherein a first human gastrointestinal segment is a rectum segment.

### Claim 37 (depends on 28)

The method according to claim 28, wherein the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells on the at least one bio-similar matrix environment are used to determine variations in DNA and/or RNA characteristics produced in response to the therapeutic agent.

### Claim 38 (depends on 28)

The method according to claim 28, further comprising the step of serially connecting the bio-similar matrix environment formed from the at least one mucosal tissue derived from the stomach segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the jejunum segment to the bio-similar matrix environment formed from the at least mucosal tissue derived from the ileum segment, to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the duodenum segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the ascending colon segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the transverse colon segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the sigmoid colon segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the rectum to form an in vitro model of the human gastrointestinal tract.

### Claim 39 (depends on 28)

The method according to claim 28, wherein the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cell has at least a β-1-integrin(+)cytokeratin(+) phenotype.

### Claim 40 (depends on 28)

The method according to claim 28, wherein the differentiable gastrointestinal segment-specific human stem epithelial cell-like progenitor cell has a phenotype of cytokeratin(+), β-1-integrin(+), defensin-5(+), trefoil factor-3(+), mucin-2(+), chomogranin-A(+), intestinal alkaline phosphatase(+), lysozyme(+).

### Claim 41

A method to identify therapeutic targets useful in treating inflammatory diseases of the gastrointestinal tract, the method comprising the steps:
(a) isolating differentiable gastrointestinal segment-specific human epithelial stem-cell-like progenitor cells from at least one human mucosal tissue derived from at least one human gastrointestinal segment;
(b) cultivating the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells on at least one bio-similar matrix environment formed from the at least one human mucosal tissue derived from the at least one human gastrointestinal segment;
(c) exposing the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells on the at least one bio-similar matrix environment to a therapeutic agent;
(d) analyzing the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells on the at least one bio-similar matrix environment exposed to the therapeutic agent to identify at least one marker as a therapeutic target.

### Claim 42 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is a stomach segment.

### Claim 43 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is a jejunum segment.

### Claim 44 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is an ileum segment.

### Claim 45 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is a duodenum segment.

### Claim 46 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is an ascending colon segment.

### Claim 47 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is a transverse colon segment.

### Claim 48 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is a sigmoid colon segment.

### Claim 49 (depends on 41)

The method according to claim 41, wherein a first human gastrointestinal segment is a rectum segment.

### Claim 50 (depends on 41)

The method according to claim 41, wherein the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cells on the at least one bio-similar matrix environment are used to determine variations in DNA and/or RNA characteristics produced in response to the therapeutic agent.

### Claim 51 (depends on 41)

The method according to claim 41, further comprising the steps of between step (b) and step (c), serially connecting the bio-similar matrix environment formed from the at least one mucosal tissue derived from the stomach segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the jejunum segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the ileum segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the duodenum segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the ascending colon segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the transverse colon segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the sigmoid colon segment to the bio-similar matrix environment formed from the at least one mucosal tissue derived from the rectum to form an in vitro model of the human gastrointestinal tract; and in step (c) of the method, serially administering the therapeutic agent to the differentiable gastrointestinal segment-specific human stem-cell-like progenitor cells isolated from a human mucosal tissue derived from a human gastrointestinal segment on the serially connected biosimilar matrix environments.

### Claim 52 (depends on 41)

The method according to claim 41, wherein the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cell has at least a β-1-integrin(+)cytokeratin(+) phenotype.

### Claim 53 (depends on 41)

The method according to claim 41, wherein the differentiable gastrointestinal segment-specific human epithelial stem cell-like progenitor cell has a phenotype of cytokeratin(+), β-1-integrin(+), defensin-5(+), trefoil factor-3(+), mucin-2(+), chomogranin-A(+), intestinal alkaline phosphatase(+), lysozyme(+).
